ICORG’s 4th NEJM Publication is now available and it’s exciting news for some Lung Cancer patients.
The study [ICORG 10-18] investigated Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. It concluded that Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non–small-cell lung cancer with ALK rearrangement.
The ICORG Principal Investigator was Prof. Ken O’Byrne. Click here to view the abstract .